Harpoon Therapeutics, Inc. – NASDAQ:HARP
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Harpoon Therapeutics stock price monthly change
+0.67%
month
Harpoon Therapeutics stock price quarterly change
+256.24%
quarter
Harpoon Therapeutics stock price yearly change
+1913.39%
year
Harpoon Therapeutics key metrics
Market Cap | 865.07M |
Enterprise value | N/A |
P/E | -0.35 |
EV/Sales | -0.29 |
EV/EBITDA | 0.13 |
Price/Sales | 0.47 |
Price/Book | 4.04 |
PEG ratio | N/A |
EPS | -8.79 |
Revenue | 37.34M |
EBITDA | -36.67M |
Income | -30.86M |
Revenue Q/Q | -67.33% |
Revenue Y/Y | 16.14% |
Profit margin | -228.52% |
Oper. margin | -229.92% |
Gross margin | 18% |
EBIT margin | -229.92% |
EBITDA margin | -98.2% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHarpoon Therapeutics stock price history
Harpoon Therapeutics stock forecast
Harpoon Therapeutics financial statements
| Dec 2022 | 4.08M | -18.07M | -442.04% |
|---|---|---|---|
| Mar 2023 | 8.58M | -12.04M | -140.38% |
| Jun 2023 | 20.22M | 1.06M | 5.25% |
| Sep 2023 | 4.44M | -1.80M | -40.51% |
| 2025 | 18.81M | -9.25M | -49.19% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 73729000 | 68.33M | 92.68% |
|---|---|---|---|
| Mar 2023 | 80809000 | 80.09M | 99.12% |
| Jun 2023 | 63199000 | 60.20M | 95.26% |
| Sep 2023 | 47578000 | 43.03M | 90.46% |
| Dec 2022 | -18.39M | 14.24M | 5.38M |
|---|---|---|---|
| Mar 2023 | -19.28M | 2.43M | 26.61M |
| Jun 2023 | -15.17M | -12.37M | -1.03M |
| Sep 2023 | -16.52M | -1.02M | 2.03M |
Harpoon Therapeutics alternative data
| Aug 2023 | 45 |
|---|---|
| Sep 2023 | 45 |
| Oct 2023 | 45 |
| Nov 2023 | 45 |
| Dec 2023 | 45 |
| Jan 2024 | 45 |
| Feb 2024 | 45 |
| Mar 2024 | 45 |
| Apr 2024 | 45 |
| May 2024 | 45 |
| Jun 2024 | 45 |
| Jul 2024 | 45 |
Harpoon Therapeutics other data
57.07%
-8.56%
of HARP is owned by hedge funds
18.86M
-2.81M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 3004305 | 0 |
| Oct 2023 | 4630500 | 0 |
| Patent |
|---|
Application Filling date: 14 May 2020 Issue date: 25 Aug 2022 |
Application Filling date: 14 Sep 2021 Issue date: 14 Apr 2022 |
Application Filling date: 14 May 2019 Issue date: 24 Feb 2022 |
Application Filling date: 20 Sep 2019 Issue date: 20 Jan 2022 |
Grant Filling date: 19 Feb 2021 Issue date: 23 Nov 2021 |
Application Filling date: 20 Sep 2019 Issue date: 18 Nov 2021 |
Grant Filling date: 12 Oct 2018 Issue date: 5 Oct 2021 |
Application Filling date: 14 May 2019 Issue date: 23 Sep 2021 |
Application Filling date: 14 May 2019 Issue date: 16 Sep 2021 |
Application Filling date: 14 May 2019 Issue date: 2 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2020 10 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q4 2019 13 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Natalie R. Sacks M.D. (1965) Chief Medical Offer | $633,350 |
| Ms. Georgia L. Erbez (1967) Chief Financial Officer | $554,550 |
Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
Harpoon Therapeutics: T-Cell Engager Platform For Immune-Related Disease
-
When is Harpoon Therapeutics's next earnings date?
Unfortunately, Harpoon Therapeutics's (HARP) next earnings date is currently unknown.
-
Does Harpoon Therapeutics pay dividends?
No, Harpoon Therapeutics does not pay dividends.
-
How much money does Harpoon Therapeutics make?
Harpoon Therapeutics has a market capitalization of 865.07M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.92% to 31.92M US dollars.
-
What is Harpoon Therapeutics's stock symbol?
Harpoon Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HARP".
-
What is Harpoon Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Harpoon Therapeutics?
Shares of Harpoon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Harpoon Therapeutics's key executives?
Harpoon Therapeutics's management team includes the following people:
- Dr. Natalie R. Sacks M.D. Chief Medical Offer(age: 60, pay: $633,350)
- Ms. Georgia L. Erbez Chief Financial Officer(age: 58, pay: $554,550)
-
How many employees does Harpoon Therapeutics have?
As Jul 2024, Harpoon Therapeutics employs 45 workers.
-
When Harpoon Therapeutics went public?
Harpoon Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 8 Feb 2019.
-
What is Harpoon Therapeutics's official website?
The official website for Harpoon Therapeutics is harpoontx.com.
-
Where are Harpoon Therapeutics's headquarters?
Harpoon Therapeutics is headquartered at 131 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Harpoon Therapeutics?
Harpoon Therapeutics's mailing address is 131 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 04437400.
Harpoon Therapeutics company profile:
Harpoon Therapeutics, Inc.
harpoontx.comExchange:
NASDAQ
Full time employees:
45
Industry:
Biotechnology
Sector:
Healthcare
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
131 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001708493
ISIN: US41358P2056
CUSIP: 41358P106
